Individualizing Strategies for Chronic Hepatitis B—What Should We Do About Patients in the Gray Zone?
  • CE

Current HBV treatment paradigms are being challenged, particularly when it comes to avoiding treatment for patients who fall into the so-called gray zone. Here’s my take on the risk vs benefit assessment for HBV treatment in this setting.
person default
Carla Coffin, MD
Registered Nurses: 0.25 Nursing contact hours
Pharmacists: 0.25 contact hours (0.025 CEUs)
Released: June 21, 2022 Expiration: June 20, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify the most appropriate management strategy for each individual patient with HBV

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Carla Coffin, MD

Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of Calgary
Medical Director of Calgary Liver Unit
Division of Gastroenterology and Hepatology
Department of Medicine
Foothills Medical Centre
Calgary, Alberta, Canada

Carla S. Coffin, MD, MSc: consultant/advisor/speaker: Altimmune; research support: Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Julie Skowronski, NP
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, BCACP , BCPS, FASHP, FCCP, has disclosed that she has individual publicly traded stocks and stock options from Abbott Laboratories, Becton Dickinson, Johnson & Johnson, and Merck & Co., Inc. (divested in 10/2020).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with or at risk of viral hepatitis.

Goal

The goal of this activity is to improve learners’ competence in addressing key challenges in the management of persons with or at risk of hepatitis B, hepatitis C, and/or hepatitis delta.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-158-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 21, 2022, through June 20, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Professor Graham Foster shares his approach to the management of hepatitis B in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: November 18, 2022

Patients and expert faculty discuss HBV misconceptions and how they impact patient engagement in care, from Clinical Care Options (CCO)

person default Janet Afoakwah, MPH person default William Amiteye person default Bright Ansah Patricia D. Jones, MD, MSCR Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: November 14, 2022 Expired: November 13, 2023

Patients and expert faculty discuss HBV misconceptions and how they impact patient engagement in care, from Clinical Care Options (CCO).

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD person default Melinda Tran person default Thuan Vu, MD Jennifer Wild, MS, BSN, RN, OCN Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: October 13, 2022 Expired: October 12, 2023

Dr Nancy Reau defines what older means in the context of HBV infection and discusses monitoring and treatment options, from Clinical Care Options (CCO)

Nancy Reau, MD Released: October 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings